| Management target | Revenue 11.0% 2034E |
|---|
| Revenue growth | 17% YoY |
|---|---|
| Margins | EBITDA margin expanded 210 bps to 25.2%. |
| Demand visibility | Sustained momentum in specialty and wellness segments. |
| Management confidence | High; outperforming growth guidance due to network expansion. |
Growth
Revenue grew 17% YoY; PAT increased 26% to INR 57 Cr; Patient and test volumes grew 10% and 11% respectively.
Outlook
Metropolis 3.0 strategy focuses on AI, genomics, and Tier-3+ expansion; network includes 209 labs and 5,000+ service points.
Risks
Highly fragmented market (85% unorganised/hospital-based); continued competition from digital and chain-based diagnostic players.
Last quarter's promises, checked
Delivered
- Organic revenue growth 12-13% → delivered 13.7% (= BEAT)
- Core Diagnostics EBITDA -2% to high-single-digit → delivered high-single-digit (= BEAT)
- Expand presence to 750+ towns → delivered 750+ towns (= BEAT)
Partly delivered
- EBITDA margin 125-150 bps improvement → delivered 210 bps (= BEAT but current call is Q1 vs FY guidance)
Investor Presentation filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹541.45
- Market cap
- ₹11,233 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 55.7×Sector 53.1×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Merger & Restructuring Worth ₹1.25 Cr
Metropolis Healthcare transferred its External Quality Assessment Services Division to subsidiary MQSPL for ₹1.25 Crore. The transfer was executed via a slump sale.
- Value
- ₹1.25 Cr
Metropolis Healthcare Merger & Restructuring Worth ₹0.01 Cr
Metropolis Healthcare's subsidiary, MQSPL, will issue 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) to Dr. Puneet Kumar Nigam. Post-conversion, MQSPL will remain a subsidiary.
- Value
- ₹0.01 Cr
Metropolis Healthcare Annual General Meeting
Metropolis Healthcare held its 26th Annual General Meeting on August 18, 2026. Shareholders reviewed financial statements and confirmed previous interim dividend payments.